Aratana Therapeutics Financials

Aratana Therapeutics Stock Summary

Aratana Therapeutics competes with Summit Materials, US GoldMining, Golden Energy, Axcelis Technologies, and Newpark Resources. Aratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States. Aratana Therapeutics, Inc. was founded in 2010 and is headquartered in Leawood, Kansas. Aratana Therapeutics operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 83 people.

Aratana Therapeutics Key Financial Ratios

Generally speaking, Aratana Therapeutics' financial ratios allow both analysts and investors to convert raw data from Aratana Therapeutics' financial statements into concise, actionable information that can be used to evaluate the performance of Aratana Therapeutics over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Aratana Therapeutics reports annually and quarterly.

Aratana Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Aratana Therapeutics's current stock value. Our valuation model uses many indicators to compare Aratana Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Aratana Therapeutics competition to find correlations between indicators driving Aratana Therapeutics's intrinsic value. More Info.Aratana Therapeutics is considered to be number one stock in return on equity category among related companies. It is considered to be number one stock in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Aratana Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Aratana Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Aratana Therapeutics' earnings, one of the primary drivers of an investment's value.

Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

If you are still planning to invest in Aratana Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aratana Therapeutics' history and understand the potential risks before investing.